Bristol Myers Squibb (CELG-RI) Cash & Current Investments (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has reported Cash & Current Investments for 18 consecutive years, with $11.1 billion the latest figure, recorded in Q2 2026.

• In Q2 2026, Cash & Current Investments fell 18.64% year-over-year to $11.1 billion; the TTM figure through Jun 2026 stood at $11.1 billion (down 18.64% YoY), while the FY2025 annual figure was $10.7 billion, down 1.71% from the prior year.
• Cash & Current Investments grew to $11.1 billion in Q2 2026 per CELG-RI's latest filing, from $10.5 billion in the prior quarter.
• Across five years, Cash & Current Investments topped out at $16.5 billion in Q3 2025 and bottomed at $6.7 billion in Q2 2024.
• Historically, Cash & Current Investments has averaged $10.8 billion across 5 years, with a median of $10.6 billion in 2025.
• Annual changes were most pronounced in 2022 — Cash & Current Investments slumped 45.46% — and 2025, when it surged 104.46%.
• Bristol Myers Squibb's Cash & Current Investments stood at $9.3 billion in 2022, then soared by 32.71% to $12.3 billion in 2023, then dropped by 11.57% to $10.9 billion in 2024, then fell by 1.71% to $10.7 billion in 2025, then gained by 3.69% to $11.1 billion in 2026.
• Business Quant data shows CELG-RI's Cash & Current Investments at $11.1 billion in Q2 2026, $10.5 billion in Q1 2026, and $10.7 billion in Q4 2025.